AI Summary of Scholarly Research

This page presents an AI-generated summary of a published research paper. The original authors did not write or review this article. [See full disclosure ↓]

Denosumab plus hip-sparing surgery showed good outcomes

Research area:medicine-clinicaloncology

What the study found

The study found that preoperative denosumab, a drug used to treat certain bone tumors, combined with curettage after surgical dislocation of the hip was associated with good clinical and functional outcomes in patients with giant cell tumor of bone in the femoral head and neck. All patients kept their native hip joints, and no local recurrence or metastasis was seen at final follow-up.

Why the authors say this matters

The authors conclude that this approach may offer a way to treat this difficult tumor location while preserving the native hip joint. The study suggests the treatment had a favorable safety profile, with no drug-related complications observed.

What the researchers tested

This was a single-center retrospective study of 14 eligible patients treated between 2016 and 2023. Each patient received three cycles of preoperative denosumab, then underwent surgical dislocation of the hip with curettage of the lesion, and was followed for 24 to 50 months.

What worked and what didn't

All 14 patients completed denosumab treatment and successful surgery. Imaging showed shrinkage of residual cavities, blurred boundaries, progressive bone sclerosis, and trabecular bone regeneration at the surgical site, and functional scores improved significantly at 1 year and were excellent in all patients. According to RECIST 1.1, 11 patients had partial remission and 3 had stable disease; no postoperative complications, local recurrence, or metastatic progression were reported.

What to keep in mind

The report includes only 14 patients from one center, so the findings are limited to this small group. The abstract does not describe a comparison group, and broader limitations are not detailed in the available summary.

Key points

  • Fourteen patients with giant cell tumor of bone in the femoral head and neck were included.
  • All patients received three preoperative cycles of denosumab before surgery.
  • All patients underwent surgical dislocation of the hip with curettage and kept their native hip joints.
  • Functional scores improved significantly after treatment, and all patients reached excellent function.
  • No postoperative complications, local recurrence, or metastatic progression were reported during follow-up.

Disclosure

Research title:
Denosumab plus hip-sparing surgery showed good outcomes
Authors:
Jimo Li, Dongfeng Cai, Zhuobin Yang, Jing Zhang, Qi Lv, Wenfeng Jin, Lvlin Zhao, Song Hong
Institutions:
Affiliated Hospital of Zunyi Medical College, Affiliated Hospital of Zunyi Medical College, Affiliated Hospital of Zunyi Medical College, Affiliated Hospital of Zunyi Medical College, Affiliated Hospital of Zunyi Medical College, Affiliated Hospital of Zunyi Medical College, Beijing Jishuitan Hospital, Zunyi Medical University
Publication date:
2026-01-08
OpenAlex record:
View
AI provenance: This post was generated by gpt-5.4-mini-2026-03-17 (OpenAI). The original authors did not write or review this post.